Central Laboratory Biomarker Service Human Immune Inflammatory Cell Drug Action Services

Aeirtec's reputation for quality and reliability is demonstrated by the current integration of their central laboratory multiplex-ELISA activity into the service provision of large clinical contract research organisations (CROs) in USA and Europe; in phases I to III and post marketing surveillance.

Aeirtec has 20 years experience in providing clinical study design and conduct, and a central laboratory service for multiplex ELISA biomarker measurement (mediator, chemokine, cytokine, growth factor, release products, and enzyme assay) in clinical trial blood-serum, -plasma and other bodily fluid samples.

Within our service, the central laboratory engages in study design of multiple- biomarker strategies. The cost effective simultaneous assay of multiple biomarkers (multiplex assay) in blood-serum, -plasma and other bodily fluids has been optimised at Aeirtec to increase study power for clinical efficacy detection (click here for further information).
Aeirtec's extensive understanding of clinical-disease and relevance of clinical biomarkers is also applied through use of human disease cells and tissues in preclinical drug efficacy studies in which we integrate our central laboratory for multiplex ELISA biomarker measurement (cytokine, growth factor, enzyme, chemokine, release products mediator assay).

Aeirtec's robust analysis platform technology works with clients in drug discovery to ensure biomarker-derived measurement of drug efficacy that is cost and time-efficient; while maintaining accuracy and precision through validation.

Ensuring clinical trial data accuracy and precision is critical for retention of potential for observation of clinical efficacy. Aeirtec's clinical trial central laboratory service multiplex-ELISA assay facility has therefore optimized data acquisition and value to maximize potential clinical trial power and endpoint significance (cancer markers, cytokine, chemokine, growth factor, enzyme, blood release products and mediators).

In many cases, commercially available kits to simultaneously measure multiple biomarkers do not include specific markers, or marker combinations required by a client clinical trial design. Aeirtec therefore also provides validated custom multiple analyte profiling and conducts both GLP and non-GLP compliant biomarker studies according to client requirements.

Aeirtec has been engaged in multiplex marker measurement in the following range of diseases: oncology including, solid tumor (e.g. lung cancer and breast cancer) and leukemia, autoimmune (e.g. rheumatoid arthritis), and inflammatory disease (osteoarthritis), immune disorders, respiratory (COPD), musculoskeletal, allergy, rhinitis and asthma, gastrointestinal (inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS)), cardiovascular, metabolic and endocrine (diabetes), central nervous system (CNS) and dermatology (eczema, psoriasis).